Literature DB >> 33790693

Analysis of Inflammatory Mediator Profiles in Sepsis Patients Reveals That Extracellular Histones Are Strongly Elevated in Nonsurvivors.

Tanja Eichhorn1, Ingrid Linsberger1, Lucia Lauková2, Carla Tripisciano1, Birgit Fendl1, René Weiss1, Franz König3, Gerhard Valicek4, Georg Miestinger4, Christoph Hörmann4, Viktoria Weber1,2.   

Abstract

The timely recognition of sepsis and the prediction of its clinical course are challenging due to the complex molecular mechanisms leading to organ failure and to the heterogeneity of sepsis patients. Treatment strategies relying on a "one-fits-all" approach have failed to reduce mortality, suggesting that therapeutic targets differ between patient subgroups and highlighting the need for accurate analysis of the molecular cascades to assess the highly variable host response. Here, we characterized a panel of 44 inflammatory mediators, including cytokines, chemokines, damage-associated molecular patterns, and coagulation-related factors, as well as markers of endothelial activation in 30 patients suffering from renal failure in the course of sepsis. All patients received continuous veno-venous hemodialysis with either high cut-off filters or with standard filters, and mediators were quantified for all patients at the initiation of dialysis and after 24 h and 48 h. Mediator concentrations in individual patients ranged widely, demonstrating the heterogeneity of sepsis patients. None of the mediators correlated with SAPS III or TISS scores. The overall in-hospital mortality of the study population was 56.7% (57.1% vs. 56.3% for high cut-off vs. standard filter). The two filter groups differed regarding most of the mediator levels at baseline, prohibiting conclusions regarding the effect of standard filters versus high cut-off filters on mediator depletion. The elevation and correlation of damage-associated molecular patterns and markers of endothelial activation gave evidence of severe tissue damage. In particular, extracellular histones were strongly increased and were almost 30-fold higher in nonsurvivors as compared to survivors, indicating their diagnostic and prognostic potential.
Copyright © 2021 Tanja Eichhorn et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33790693      PMCID: PMC7994100          DOI: 10.1155/2021/8395048

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  63 in total

1.  Endothelial cell-specific molecule-1/endocan: Diagnostic and prognostic value in patients suffering from severe sepsis and septic shock.

Authors:  Dominic Pauly; Sonja Hamed; Michael Behnes; Dominic Lepiorz; Siegfried Lang; Ibrahim Akin; Martin Borggrefe; Thomas Bertsch; Ursula Hoffmann
Journal:  J Crit Care       Date:  2015-09-25       Impact factor: 3.425

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

3.  Recognizing Sepsis as a Global Health Priority - A WHO Resolution.

Authors:  Konrad Reinhart; Ron Daniels; Niranjan Kissoon; Flavia R Machado; Raymond D Schachter; Simon Finfer
Journal:  N Engl J Med       Date:  2017-06-28       Impact factor: 91.245

4.  Histones induce rapid and profound thrombocytopenia in mice.

Authors:  Tobias A Fuchs; Ashish A Bhandari; Denisa D Wagner
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

5.  Why have clinical trials in sepsis failed?

Authors:  John C Marshall
Journal:  Trends Mol Med       Date:  2014-02-24       Impact factor: 11.951

6.  A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis.

Authors:  David Andaluz-Ojeda; Felipe Bobillo; Verónica Iglesias; Raquel Almansa; Lucía Rico; Francisco Gandía; Salvador Resino; Eduardo Tamayo; Raul Ortiz de Lejarazu; Jesús F Bermejo-Martin
Journal:  Cytokine       Date:  2011-12-23       Impact factor: 3.861

7.  Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis.

Authors:  Andreas Oberholzer; Sonia M Souza; Sven K Tschoeke; Caroline Oberholzer; Amer Abouhamze; John P Pribble; Lyle L Moldawer
Journal:  Shock       Date:  2005-06       Impact factor: 3.454

8.  Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines.

Authors:  Amanda Walborn; Debra Hoppensteadt; Daneyal Syed; Michael Mosier; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2017-05-17       Impact factor: 2.389

9.  Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis.

Authors:  Fernando A Bozza; Jorge I Salluh; André M Japiassu; Marcio Soares; Edson F Assis; Rachel N Gomes; Marcelo T Bozza; Hugo C Castro-Faria-Neto; Patrícia T Bozza
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 10.  The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?

Authors:  Jonathan S Boomer; Jonathan M Green; Richard S Hotchkiss
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

View more
  2 in total

Review 1.  Activated Platelets and Platelet-Derived Extracellular Vesicles Mediate COVID-19-Associated Immunothrombosis.

Authors:  Marie Ebeyer-Masotta; Tanja Eichhorn; René Weiss; Lucia Lauková; Viktoria Weber
Journal:  Front Cell Dev Biol       Date:  2022-07-06

2.  Heparin-Functionalized Adsorbents Eliminate Central Effectors of Immunothrombosis, including Platelet Factor 4, High-Mobility Group Box 1 Protein and Histones.

Authors:  Marie Ebeyer-Masotta; Tanja Eichhorn; René Weiss; Vladislav Semak; Lucia Lauková; Michael B Fischer; Viktoria Weber
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.